Id: acc4264
Group: 1sens
Protein: PDGFRbeta
Gene Symbol: PDGFRB
Protein Id: P09619
Protein Name: PGFRB_HUMAN
PTM: phosphorylation
Site: Tyr857
Site Sequence: ARDIMRDSNYISKGSTFLPLK
Disease Category: Cancer
Disease: Gastric Cancer
Disease Subtype: gastrointestinal stromal tumor
Disease Cellline: GIST–T1
Disease Info:
Drug: dasatinib
Drug Info: Dasatinib is a medication used in the treatment of certain types of leukemia. It functions as a tyrosine - kinase inhibitor to block abnormal protein signaling in cancer cells.
Effect: inhibit
Effect Info: "As a proteasome inhibitor, bortezomib can significantly inhibit the viability of dasatinib - treated GIST - T1 cells and promote their apoptosis. When GIST - T1 cells are treated with dasatinib alone, the cells show little cytotoxic response to dasatinib. This is because the c - KIT upregulation caused by dasatinib itself can interfere with dasatinib's inhibitory effect on the phosphorylation of c - KIT and platelet - derived growth factor receptor β (PDGFRβ). "
Note:
Score: 5.0
Pubmed(PMID): 25737303
Sentence Index:
Sentence:

Sequence & Structure:

MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPVVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFVPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFSGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGNEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDHQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDSSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVLELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNVTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILALVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQLVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGPHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNALPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVPSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLVKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLGGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLERLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDNDYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQVEPEPELEQLPDSGCPAPRAEAEDSFL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
PDGFRB MIDOSTAURIN Platelet-derived growth factor receptor inhibitor 4 - acute myeloid leukemia FDA
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 - acute lymphoblastic leukemia DailyMed
DailyMed
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 Unknown status acute lymphoblastic leukemia ClinicalTrials
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 Completed chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
PDGFRB IMATINIB MESYLATE Platelet-derived growth factor receptor beta inhibitor 4 - chronic myelogenous leukemia DailyMed
DailyMed
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 - chronic myelogenous leukemia DailyMed
DailyMed
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 Recruiting chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
ClinicalTrials
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 Unknown status chronic myelogenous leukemia ClinicalTrials
PDGFRB IMATINIB MESYLATE Platelet-derived growth factor receptor beta inhibitor 4 Completed chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
PDGFRB REGORAFENIB Platelet-derived growth factor receptor inhibitor 4 - neoplasm ATC
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 - neoplasm ATC
PDGFRB DASATINIB Platelet-derived growth factor receptor beta inhibitor 4 - neoplasm ATC
PDGFRB MASITINIB Platelet-derived growth factor receptor inhibitor 4 - neoplasm ATC
PDGFRB TIVOZANIB HYDROCHLORIDE Platelet-derived growth factor receptor beta inhibitor 4 - renal cell carcinoma DailyMed
FDA
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 Completed neoplasm ClinicalTrials
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 - renal cell carcinoma DailyMed
EMA
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 Completed renal cell carcinoma ClinicalTrials
ClinicalTrials
PDGFRB MIDOSTAURIN Platelet-derived growth factor receptor inhibitor 4 - neoplasm ATC
PDGFRB SORAFENIB TOSYLATE Platelet-derived growth factor receptor beta inhibitor 4 - renal cell carcinoma DailyMed
PDGFRB SUNITINIB MALATE Platelet-derived growth factor receptor inhibitor 4 - renal cell carcinoma DailyMed
PDGFRB PAZOPANIB HYDROCHLORIDE Platelet-derived growth factor receptor inhibitor 4 - renal cell carcinoma FDA
DailyMed
PDGFRB SUNITINIB MALATE Platelet-derived growth factor receptor inhibitor 4 Completed renal cell carcinoma ClinicalTrials
PDGFRB PAZOPANIB HYDROCHLORIDE Platelet-derived growth factor receptor inhibitor 4 - sarcoma DailyMed
FDA
PDGFRB NINTEDANIB ESYLATE Platelet-derived growth factor receptor inhibitor 4 - systemic scleroderma DailyMed
PDGFRB SUNITINIB Platelet-derived growth factor receptor inhibitor 4 Terminated renal cell carcinoma ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

PDGFRB-Ser641
Cancer Intensity
BRCA -0.94
COAD
HGSC
ccRCC -1.536
GBM
HNSC 0.459
LUAD 1.02
LUSC 0.284
non_ccRCC
PDAC -0.409
UCEC 1.122
PDGFRB-Ser684
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.048
GBM
HNSC -0.975
LUAD
LUSC 1.023
non_ccRCC
PDAC
UCEC
PDGFRB-Thr635
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.707
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: